Two Incretin Receptors, Two Separate Target Tissues
Before treatment, GIP and GLP-1 receptors act independently.
- Pancreas · fat: GIP receptor tissue (islet beta cells, adipocytes)
- Brain · gut: GLP-1 receptor tissue (hypothalamus, vagal afferents)
- 0%: Baseline occupancy (no exogenous agonist present)
- ~2 min: Native incretin half-life (degraded by DPP-4 rapidly)
Why two separate incretin systems exist
Short placeholder: GIP and GLP-1 evolved as distinct post-meal signals.
GIP: fat and glucose handling.
GLP-1: satiety and gastric slowing.
The single-agonist limitation
Placeholder: older drugs engage only the GLP-1 receptor arm.
Tirzepatide — One Peptide Engineered for Two Receptors
A single 39-amino-acid peptide binds GIP-R and GLP-1-R.
- GIP/GLP-1 dual agonist: Molecule class (first-in-class, approved 2022)
- 39 aa: Peptide length (engineered from native GIP backbone)
- ~5 days: Half-life (fatty-acid acylation, once-weekly dosing)
- Simultaneous: Binding mode (both receptor arms engaged at once)
Engineering a dual-receptor peptide
Placeholder: backbone modified so one molecule fits two receptors.
Pharmacokinetics of weekly dosing
Placeholder: albumin binding extends exposure across the whole week.
Two Arms, Two Downstream Pathways, Fired Together
GLP-1 arm suppresses appetite; GIP arm improves insulin sensitivity.
- Appetite · gastric rate: GLP-1 arm target (hypothalamus + vagal signaling)
- Insulin sensitivity: GIP arm target (adipose + beta-cell function)
- Slowed: Gastric emptying Δ (prolongs fullness signal duration)
- Enhanced: Lipolysis effect (GIP arm shifts fat metabolism)
GLP-1 receptor arm — appetite and gastric signaling
Placeholder: slower gastric emptying plus hypothalamic satiety drive.
GIP receptor arm — metabolic and adipose signaling
Placeholder: improved insulin sensitivity and fat-tissue metabolism.
Combined Pathways Outperform Either Receptor Alone
Overlapping GIP and GLP-1 signaling produces a larger net effect.
- Additive+: Combined effect score (exceeds simple sum of parts)
- Larger: Caloric deficit (vs single-receptor comparator dose)
- Improved: Glycemic control (HbA1c reductions reported in trials)
- Cross-pathway: Synergy mechanism (shared downstream signaling nodes)
Why dual activation is synergistic, not additive
Placeholder: overlapping neural and metabolic circuits amplify outcome.
Clinical signal for synergy
Placeholder: trial data shows effect beyond single-pathway prediction.
Dual Agonism vs Single-Agonist GLP-1 Therapy
Tirzepatide trial arms show greater weight loss than GLP-1-only drugs.
- ~20–22%: Tirzepatide (high dose) (mean body-weight loss, 72 wk)
- ~12–15%: Single-agonist GLP-1 (mean body-weight loss, comparable term)
- +40–60%: Relative advantage (more weight loss vs single-agonist)
- Once weekly: Dosing frequency (both drug classes, similar regimen)
Head-to-head trajectory over therapy weeks
Placeholder: dual-agonist curve separates from single-agonist curve early.
Interpreting the comparative advantage
Placeholder: two receptor pathways beat one at matched dose.
Dual agonist vs single-agonist — placeholder comparison